###begin article-title 0
CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 231 236 <span type="species:ncbi:9606">human</span>
Opioid agonists have a broad range of effects on cells of the immune system, including modulation of the inflammatory response, and opioid and chemokine receptors are co-expressed by many white cells. Hetero-oligomerization of the human DOP opioid and chemokine CXCR2 receptors could be detected following their co-expression by each of co-immunoprecipitation, three different resonance energy transfer techniques and the construction of pairs of individually inactive but potentially complementary receptor G-protein alpha subunit fusion proteins. Although DOP receptor agonists and a CXCR2 antagonist had no inherent affinity for the alternative receptor when either receptor was expressed individually, use of cells that expressed a DOP opioid receptor construct constitutively, and in which expression of a CXCR2 receptor construct could be regulated, demonstrated that the CXCR2 antagonist enhanced the function of DOP receptor agonists only in the presence of CXCR2. This effect was observed for both enkephalin- and alkaloid-based opioid agonists, and the effective concentrations of the CXCR2 antagonist reflected CXCR2 receptor occupancy. Entirely equivalent results were obtained in cells in which the native DOP opioid receptor was expressed constitutively and in which expression of the isolated CXCR2 receptor could be induced. These results indicate that a CXCR2 receptor antagonist can enhance the function of agonists at a receptor for which it has no inherent direct affinity by acting as an allosteric regulator of a receptor that is a heterodimer partner for the CXCR2 receptor. These results have novel and important implications for the development and use of small-molecule therapeutics.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 823 824 823 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1049 1050 1049 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1051 1052 1051 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1187 1188 1187 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1189 1191 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1578 1580 1578 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1739 1741 1739 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1548 1553 <span type="species:ncbi:9606">human</span>
It has become increasingly clear in recent times that opioid agonists have a broad range of effects on cells of the immune system, including modulation of the inflammatory response [1]. Opioid receptor levels are regulated by peripheral inflammation [2], and it is thought that highly peripherally selective opioid agonists may provide a therapeutic approach for the treatment of inflammation and inflammatory pain (see [3] for review). Opioids function via three molecularly defined receptor subtypes, the DOP, KOP and MOP receptors [4]. These are all members of the rhodopsin-like family of GPCRs (G-protein-coupled receptors). As well as their characterized expression patterns in the central and peripheral nervous systems they are expressed on a wide range of white blood cells, including macrophages and neutrophils [5]. Various opioid agonists are known to produce chemotactic responses in white cells, and to modulate chemotaxis induced by a range of chemokines. Chemokines and their receptors are also integrators of pain and inflammation [6-8] and there is a clear capacity for heterologous modification and desensitization between co-expressed chemokine and opioid receptors [9-11]. Receptors for chemokine ligands also belong to the rhodopsin-like GPCR family, and one further potential mechanism that may contribute to the effects outlined above is direct interactions between chemokine and opioid receptors. At least for the CCR5 chemokine receptor, a capacity to co-immunoprecipitate each of the DOP, KOP and MOP receptors from both human and monkey lymphocytes [12] provided preliminary evidence of such interactions, and direct protein-protein contacts between CCR5 and the MOP receptor have been confirmed independently [13].
###end p 4
###begin p 5
###xml 47 49 47 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 361 368 361 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 426 431 <span type="species:ncbi:9606">human</span>
The closely related CXCR1 and CXCR2 receptors [14] share a common agonist ligand in IL-8 (interleukin 8; also called CXCL8). They are widely co-expressed on immune cells, including neutrophils, CD8(+) T-cells and mast cells, and allosteric inhibitors of these receptors have been suggested to offer a general means to inhibit polymorphonuclear cell recruitment in vivo [15]. Opioid agonists inhibit IL-8-induced chemotaxis of human neutrophils, and opioid agonists are able to cause phosphorylation of CXCR1 and CXCR2 receptors [9]. Interestingly, CXCR2, but not CXCR1, is expressed by a variety of neurones and astrocytes [14] and may be involved in the directed migration of specific subsets of neurones.
###end p 5
###begin p 6
###xml 184 191 184 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 951 953 951 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 954 956 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1077 1079 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
Although it was believed for many years that GPCRs functioned exclusively as monomers, a growing consensus has challenged this view. Indeed, it is now widely believed that the minimal in situ functional unit for a GPCR is a dimer and that further, higher-order, oligomeric structures may exist [16-19]. Much evidence suggests that for many GPCRs dimerization/oligomerization occurs during synthesis and maturation within the endoplasmic reticulum [20,21] prior to plasma membrane delivery. This model would explain why many GPCRs appear to be constitutively formed dimers/oligomers. It is also increasingly accepted that at least certain GPCRs have the capacity to form heterodimers/oligomers (i.e. dimers formed between two different GPCR gene products) [16,22]. Such heterodimers/oligomers may have distinct functional and pharmacological properties and have been suggested to offer novel sets of targets for therapeutic small-molecule drug design [22,23]. Although the CXCR1 receptor was originally reported not to homodimerize or to heterodimerize with the CXCR2 receptor [24], Wilson et al. [21] recently employed a wide range of biochemical and biophysical approaches to demonstrate the capacity of both CXCR1 and CXCR2 to homodimerize and to show that these two GPCRs were able to form heterodimers as effectively as homodimers.
###end p 6
###begin p 7
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 675 678 675 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
It has recently been demonstrated that selective ligands at pairs of GPCRs that heterodimerize have the potential to modulate ligand effects at the partner GPCR via allosterism (see [25] for review). Studies on heterodimerization between the CCR2b and CCR5 chemokine receptors have demonstrated the ability of CCR5-specific ligands, that are unable to compete for the binding of the CCR2 selective ligand MCP-1 (monocyte chemoattractant protein 1) on cells expressing CCR2b alone, to prevent efficiently MCP-1 binding when the two receptors are co-expressed [26]. Similarly, co-expression of the orphan GPCR, GPR50, along with the melatonin MT1 receptor inhibits binding of [125I]melatonin to the MT1 receptor [27].
###end p 7
###begin p 8
###xml 113 118 <span type="species:ncbi:9606">human</span>
In the present study we use a range of approaches to demonstrate the capacity for heterodimerization between the human CXCR2 and DOP opioid receptors and show that a CXCR2 antagonist enhances the function of both peptide and alkaloid-based agonists at the DOP receptor via an allosteric mechanism when the two receptors are co-expressed. This is despite the CXCR2 ligand having no significant affinity to interact directly with the DOP receptor.
###end p 8
###begin title 9
EXPERIMENTAL
###end title 9
###begin title 10
Materials
###end title 10
###begin p 11
###xml 7 8 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 111 112 111 112 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sc>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 145 146 145 146 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sc>
###xml 150 153 150 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2,5</sup>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 296 297 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
[15,16-3H]Diprenorphine (50 Ci/mmol) and [35S]GTP[S] (1250 Ci/mmol) were from PerkinElmer Life Science. DADLE (D-Ala2, Leu5-enkephalin), DPDPE ([D-Pen2,5]-enkephalin) and pertussis toxin were from Sigma-Aldrich. SB225002 was from Calbiochem, and SNC162 [28] was from Tocris. All reagents for BRET2 (bioluminescence resonance energy transfer) studies were from Packard Biosciences.
###end p 11
###begin title 12
Antibodies/antisera
###end title 12
###begin p 13
###xml 15 16 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 10 19 10 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;<italic>i</italic>1&#8211;2</sub>
###xml 66 68 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
###xml 144 150 <span type="species:ncbi:9986">rabbit</span>
The anti-Galphai1-2 antiserum (SG) has been described previously [29]. The mouse monoclonal anti-FLAG antibody (M2) was from Sigma-Aldrich. The rabbit polyclonal anti-c-Myc antiserum was from Cell Signalling Technology.
###end p 13
###begin title 14
Molecular Constructs
###end title 14
###begin p 15
###xml 12 19 12 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 80 87 76 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 110 117 102 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 162 164 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 186 193 174 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 210 217 194 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i1</sub>
###xml 232 239 212 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 263 270 239 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 417 424 389 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 468 470 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 520 522 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 592 599 564 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 43 48 <span type="species:ncbi:9606">human</span>
hDOP-C352I Galphai2 (where h indicates the human form), V150E,V154D hDOP-C352I Galphai2 and hDOP-G204A,C352I Galphai2 were constructed as in Pascal and Milligan [30], except that C352I Galphai2 replaced C351I Galphai1. CXCR2-C352I Galphai2 and I148E CXCR2-C352I Galphai2 were constructed using similar approaches. FLAG-hCXCR2, c-Myc-hCXCR2 and forms of the CXCR2 C-terminally tagged with auto-fluorescent proteins or Renilla luciferase have been described previously [21], as have the equivalent modified forms of hDOP [31]. The nomenclature for the molecular constructs employed is shown in Table 1.
###end p 15
###begin title 16
Characteristics of the molecular constructs employed
###end title 16
###begin title 17
Fluorescent microscopy and FRET (fluorescence resonance energy transfer) imaging in living cells
###end title 17
###begin p 18
###xml 25 26 25 26 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sc>
###xml 322 323 322 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 334 335 334 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 359 360 359 360 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sc>
Cells were grown on poly-D-lysine-treated coverslips and transiently transfected with appropriate eCFP (enhanced cyan fluorescent protein)/eYFP (enhanced yellow fluorescent protein) fusion proteins. Coverslips were placed into a microscope chamber containing physiological saline solution [130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 20 mM Hepes and 10 mM D-glucose (pH 7.4)]. Cells were visualized using a Nikon Eclipse TE2000-E fluorescence inverted microscope and images were obtained individually for eYFP, eCFP and FRET filter channels using an Optoscan monochromator (Cairn Research) and a dichroic mirror 86002v2bs (Chroma). The filter sets used were: eYFP (excitation: 500/5 nm; emission: 535/30 nm), eCFP (excitation: 430/12 nm; emission: 470/30 nm) and FRET (excitation: 430/12 nm; emission: 535/30 nm). The illumination time was 250 ms and binning modes 2.2. MetaMorph imaging software was used to quantify the FRET images using the sensitized FRET method. Corrected FRET was calculated using a pixel-by-pixel methodology using the equation:  where eCFP, eYFP and FRET values correspond to background corrected images obtained through the eCFP, eYFP and FRET channels. B and A correspond to the values obtained for the eCFP (donor) and eYFP (acceptor) bleedthrough co-efficients respectively, calculated using cells singly transfected with either the eCFP or eYFP protein alone. To correct the FRET levels for the various amounts of donor (eCFP) and acceptor (eYFP), normalized FRET was calculated using the equation:  where FRETc, eCFP and eYFP are equal to the fluorescence values obtained from single cells.
###end p 18
###begin title 19
Tr (time-resolved) FRET
###end title 19
###begin p 20
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 317 319 316 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3+</sup>
###xml 368 370 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 371 373 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 689 690 682 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 689 690 682 683 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 1035 1036 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1255 1256 1246 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1256 1259 1247 1250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">665</sub>
###xml 1307 1308 1298 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1308 1311 1299 1302 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">615</sub>
###xml 1359 1362 1350 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BLK</italic>
###xml 1434 1435 1425 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1550 1552 1541 1543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3+</sup>
###xml 1570 1571 1561 1562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1571 1574 1562 1565 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">665</sub>
###xml 1575 1578 1566 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BLK</italic>
###xml 1580 1581 1571 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1581 1584 1572 1575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">615</sub>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 403 407 <span type="species:ncbi:9913">calf</span>
For tr-FRET, 10 cm2 dishes of HEK (human embryonic kidney)-293 cells were transfected to express N-terminally c-Myc- or FLAG-tagged forms of hCXCR2 and/or hDOP individually or in combination. At 48 h after transfection, the cells were harvested. Cell pellets were resuspended in 200 mul of ice-cold PBS. Anti-c-Myc Eu3+ and anti-FLAG APC (allophycocyanin) antibodies [21,31] were diluted in 50% newborn calf serum/50% PBS to final concentrations of 5 nM and 15 nM respectively. Samples were mixed and incubated on a rotating wheel at room temperature (22 degreesC) for 2 h while covered in aluminium foil to minimize exposure of the fluorophores to light. Samples were centrifuged at 1000 g for 1 min and the antibody mix was removed from the cell pellet. The pellet was then washed twice in ice-cold PBS and resuspended in 250 mul of PBS. To measure the energy transfer, 40 mul of each sample was dispensed in triplicate into a black 384-well plate. Blank wells containing PBS were also included. Tr-FRET was determined using a Victor2 plate reader (Packard Bioscience). Excitation was at 340 nm and emission filters generated data representing donor (615 nm) and acceptor (665 nm) fluorescence. Normalized FRET was calculated using the equation:  where A665 is the fluorescent emission from the acceptor, D615 is the fluorescent emission from the donor and BLK represents the background reading at 665 nm from wells containing PBS. C represents the cross-talk between the donor and acceptor windows for the samples incubated with only anti-c-Myc Eu3+ and is equal to (A665-BLK)/D615.
###end p 20
###begin title 21
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Saturation BRET2 studies
###end title 21
###begin p 22
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 833 834 831 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 875 876 873 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1018 1019 1016 1017 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1111 1118 1109 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 1179 1180 1177 1178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1289 1292 1287 1290 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAX</sub>
###xml 1301 1303 1299 1301 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1322 1325 1320 1323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAX</sub>
###xml 1361 1363 1359 1361 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
In saturation BRET2 experiments, cells were transfected with a constant amount of the energy donor (Renilla luciferase) construct and varying amounts of energy acceptor [GFP2 (green fluorescent protein) construct. BRET2 was assessed using the luciferase substrate DeepBlueC in intact cells. Cells were also harvested, membranes prepared and diluted to 0.5 mg/ml. Luminescence and fluorescence measurements were then obtained to measure construct expression. Then, 50 mul of cell membranes were dispensed into white-walled 96-well plates (PerkinElmer) for luminescence measurements and black-walled 386-well plates (Costar) for fluorescence measurements. For luminescence measurement 5 muM h-coelenterazine was added and the plate was incubated at room temperature for 30 min prior to measurement at 410 nm using a Mithras LB 940. GFP2 fluorescence was assessed using a Victor2 1420 Multilabel counter (PerkinElmer). Fluorescence readings were corrected for endogenous fluorescence of HEK-293 cell membranes alone. BRET2 readings were corrected for energy transfer resulting from bleedthrough of signal from the Renilla luciferase construct expressed alone but detected in the GFP2 channel. Graphpad Prism 4 was used to analyse data using a one-site binding hyperbola equation yielding BRETMAX and BRET50 values (where BRETMAX is the maximal BRET signal and BRET50 is half the maximal BRET signal).
###end p 22
###begin title 23
Cell transfection and treatment
###end title 23
###begin p 24
HEK-293 cells were transfected transiently using Lipofectaminetrade mark reagent (Gibco Life Technologies) or Gene Juice (Novagen) and the appropriate cDNA(s) according to the manufacturer's instructions. Where appropriate, cells were treated with pertussis toxin (25 ng/ml) for 16-18 h prior to harvest.
###end p 24
###begin title 25
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
[3H]Diprenorphine binding
###end title 25
###begin p 26
###xml 92 93 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 437 438 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 572 573 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
The expression of hDOP-G-protein fusions was assessed by measuring the specific binding of [3H]diprenorphine in cell-membrane preparations. Non-specific binding was assessed by the addition of 100 muM naloxone. Samples were incubated for 1 h at 25 degreesC and bound ligand was separated from free ligand by vacuum filtration through GF/B filters pre-treated with 0.3% polyethyleneimine in TEM (10 mM Tris/HCl, 0.1 mM EDTA and 10 mM MgCl2, pH adjusted to 7.5). Bound ligand was estimated by liquid scintillation spectroscopy. Competition studies were conducted with 1 nM [3H]diprenorphine and a range of concentrations of other ligands. Data were analysed using GraphPad Prism software. Saturation data were fitted to non-linear regression curves.
###end p 26
###begin title 27
###xml 1 3 1 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
[35S]GTP[S] binding studies
###end title 27
###begin p 28
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 165 167 164 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 457 458 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 526 527 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 526 527 518 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 806 807 786 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 806 807 786 787 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 867 874 847 850 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i1</sub>
###xml 876 883 852 855 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 895 897 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1055 1057 1021 1023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
Experiments were initiated by adding the assay buffer mix [20 mM Hepes (pH 7.4), 3 mM MgCl2, 100 mM NaCl, 10 muM GDP and 0.2 mM ascorbic acid] containing 50 nCi of [35S]GTP[S] in the presence or absence of ligands to defined amounts of membranes. Non-specific binding was determined in the presence of 100 muM GTP[S]. The reaction was incubated for 15 min at 30 degreesC and terminated by adding 1 ml of ice-cold stop buffer [20 mM Hepes (pH 7.4), 3 mM MgCl2 and 100 mM NaCl]. The samples were centrifuged for 15 min at 16000 g at 4 degreesC and the resulting pellets were resuspended in solubilization buffer (100 mM Tris/HCl, 200 mM NaCl, 1 mM EDTA and 1.25% Nonidet P40, pH adjusted to 7.4) plus 0.2% SDS. Samples were pre-cleared with Pansorbin for 1 h at 4 degreesC and centrifuged for 2 min at 16000 g. Supernatant was added to a mix of Protein G and the anti-Galphai1/Galphai2 antiserum [29] and was left rotating overnight at 4 degreesC for immunoprecipitation. The immunocomplexes were washed twice with ice-cold solubilization buffer and bound [35S]GTP[S] was measured.
###end p 28
###begin title 29
Co-immunoprecipitation
###end title 29
###begin p 30
###xml 197 198 197 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 321 322 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 321 322 315 316 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 559 560 540 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 559 560 540 541 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 1015 1016 980 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1015 1016 980 981 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
Cells were resuspended in 1 ml of 1.RIPA [radio-immunoprecipitation assay; 50 mM Hepes (pH 7.4), 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 100 mM NaF, 5 mM EDTA, 0.1 mM NaPO4 and 5% ethylene glycol] buffer and rotated for 60 min at 4 degreesC to allow lysis. The samples were centrifuged at 14000 g for 10 min at 4 degreesC and the supernatant was retained. A 50 mul aliquot of a Protein G-Sepharose/PBS slurry was added to the supernatant and rotated for a further 60 min at 4 degreesC to pre-clear. Samples were centrifuged at 14000 g for 10 min at 4 degreesC. The supernatant was conserved and the protein concentration was measured using the BCA (bicinchoninic acid) assay method. Samples were equalized to 1 mug/mul. Target proteins were then immunoprecipitated from 500 mul aliquots of samples by incubation with 20 mul of Protein G-Sepharose and the appropriate antibody/antiserum overnight at 4 degreesC on a rotating wheel. Immune complexes were isolated by centrifugation at 14000 g for 1 min and washed twice with RIPA buffer. Proteins were eluted from the Protein G-Sepharose by the addition of 30-50 mul of Laemmli buffer and heated for 4 min at 85 degreesC. The eluates were then loaded on to SDS/PAGE gels.
###end p 30
###begin title 31
Construction of Flp-In T-REx HEK-293 cell lines
###end title 31
###begin p 32
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 307 308 307 308 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</sc>
###xml 464 465 457 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 569 576 562 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i2&#945;</sub>
###xml 1053 1060 1032 1035 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 353 357 <span type="species:ncbi:9913">calf</span>
The basic protocol used to generate Flp-In T-REx HEK-293 cell lines that constitutively express one GPCR and can be induced to express a second has been described previously [32-34]. In brief, cells were maintained in DMEM (Dulbecco's modified Eagle's medium) without sodium pyruvate, 4500 mg/l glucose and L-glutamine supplemented with 10% (v/v) fetal calf serum, 1% antibiotic mixture and 10 mug/ml blasticidin at 37 degreesC in a humidified atmosphere of air/CO2 (19:1). To generate Flp-In T-REx HEK-293 cell lines able to inducibly express c-Myc-I148E CXCR2-C352I Gi2alpha or VSV-G-CXCR2 (where VSV-G is vesicular-stomatitis-virus glycoprotein), cells were transfected with a mixture containing the desired receptor cDNA in pcDNA5/FRT/TO vector and the pOG44 vector (1:9) using Lipofectaminetrade mark (Invitrogen) according to the manufacturer's instructions. After 48 h, the medium was changed to medium supplemented with 200 mug/ml hygromycin B to initiate selection of stably transfected cells. To constitutively express FLAG-hDOP-G204A, C352I Galphai2 or FLAG-hDOP in cell lines already capable of the induction of expression of a second construct, the appropriate cells were further transfected with the desired receptor cDNA in pcDNA3 as described above, and resistant cells were selected in the presence of 1 mg/ml G418. Resistant clones were screened for receptor expression by immunocytochemical analysis. Cells were treated with 1 mug/ml doxycycline 6-96 h before assays to induce expression of receptors and receptor constructs cloned into the Flp-In locus.
###end p 32
###begin title 33
Immunostaining protocol
###end title 33
###begin p 34
###xml 210 211 204 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cells were grown on to coverslips, and 24 h later medium was removed and the cells were incubated with 20 mM Hepes/DMEM containing the appropriate dilution of primary antibody for 40 min at 37 degreesC in 5% CO2. Following three washes with PBS, cells were fixed by incubating with 4% paraformaldehyde in PBS/5% sucrose for 10 min at room temperature. Following three further washes, cells were permeabilized with 0.15% Triton X-100/3% non-fat dried skimmed milk/PBS for 10 min. The coverslips were incubated with a secondary antibody (5 mug/ml) conjugated to an Alexa Fluor(R)-594 fluorophore. Following incubation for 1 h, cells were washed twice in 0.15% Triton X-100/3% non-fat dried skimmed milk/PBS and three times in PBS. Coverslips were then mounted on to microscope slides with 40% glycerol in PBS.
###end p 34
###begin title 35
Confocal laser scanning microscopy
###end title 35
###begin p 36
Cells were imaged using a laser scanning confocal microscope (Zeiss LSM 5 Pascal) equipped with a 63x oil-immersion Plan Fluor Apochromat objective lens with a numerical aperture of 1.4. A pinhole of 20 and an electronic zoom of 1 or 2.5 was used (Carl Zeiss). The excitation laser line for GFP and eYFP was the 488 nm argon laser with detection via a 505-530 band pass filter. Alexa Fluor(R)-594 label was excited using a 543 nm helium/neon laser and detected via a 560 nm long-pass filter. The images were manipulated using MetaMorph imaging software (version 6.1.3; Universal Imaging).
###end p 36
###begin title 37
RESULTS
###end title 37
###begin p 38
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 523 531 523 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 696 704 696 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 872 880 872 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1265 1267 1265 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1268 1270 1268 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1438 1440 1438 1440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3+</sup>
###xml 1672 1680 1672 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1846 1848 1846 1848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3+</sup>
###xml 1887 1895 1887 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2131 2139 2131 2139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2260 2262 2260 2262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 2274 2276 2274 2276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 2277 2279 2277 2279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 2480 2488 2480 2488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2662 2664 2662 2664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 2665 2667 2665 2667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 2731 2738 2731 2738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 2981 2988 2981 2988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 3014 3015 3014 3015 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 3108 3116 3108 3116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 3154 3155 3154 3155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 3181 3188 3181 3188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 3371 3379 3371 3379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 3413 3415 3413 3415 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 3500 3507 3498 3505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 3531 3532 3529 3530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 3644 3646 3642 3644 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 3681 3688 3677 3684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 3715 3716 3711 3712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 3777 3779 3773 3775 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 3797 3805 3791 3799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 92 97 <span type="species:ncbi:9606">human</span>
To examine potential interactions between the chemokine CXCR2 and DOP opioid receptors, the human forms of these receptors were modified to incorporate either the FLAG or c-Myc epitope tag sequences at the N-terminus. We have previously shown the capacity of each of these receptors to form homodimers/oligomers via co-immunoprecipitation studies [21,31]. Expression in HEK-293 cells of FLAG-hCXCR2 resulted in immunological detection in lysates of these cells of a 34 kDa polypeptide with a degree of micro-heterogeneity (Figure 1) representing differential N-glycosylation [21]. Expression of c-Myc-hDOP resulted in the presence of a c-Myc-reactive polypeptide with a molecular mass of 60 kDa (Figure 1). Only with co-expression of FLAG-hCXCR2 and c-Myc-hDOP did immunoprecipitation with an anti-FLAG antibody result in co-immunoprecipitation of c-Myc immunoreactivity (Figure 1) and, even in SDS/PAGE, such immunoreactivity migrated with sizes ranging from 60 kDa to complexes with a substantially higher apparent molecular mass. Because the N-terminal region of GPCRs that are effectively delivered to the cell surface is expected to be extracellular, we also took advantage of the introduced N-terminal tags to perform tr-FRET studies in intact HEK-293 cells [21,31] to detect protein complexes containing both receptors at the cell surface. Co-expression of c-Myc-hCXCR2 and FLAG-hDOP followed by the addition of a combination of Eu3+-labelled anti-c-Myc, to act as a long-lived energy donor, and APC-labelled anti-FLAG, to act as a potential energy acceptor, resulted in strong tr-FRET and output of light at 665 nm when samples were illuminated with 320 nm light (Figure 2A). This did not occur when HEK-293 cell populations individually expressing either c-Myc-hCXCR2 or FLAG-hDOP were combined prior to addition of the combination of Eu3+-labelled and APC-labelled antibodies (Figure 2A). Furthermore, the extent of energy transfer following co-expression of c-Myc-hCXCR2 and FLAG-hDOP was virtually the same as when c-Myc-hDOP and FLAG-hDOP were co-expressed to generate tr-FRET competent, cell-surface hDOP homodimers (Figure 2A). We have also previously shown that in-frame fusion of auto-fluorescent proteins to the C-terminus of each of hCXCR2 [21] and hDOP [31,35] does not significantly alter the function or pharmacology of these receptors. Co-expression of hCXCR2-eCFP and hDOP-eYFP resulted in a capacity to image eCFP to eYFP FRET in individual single cells (Figure 2B), providing further evidence for direct hCXCR2-hDOP interactions. Estimates of the relative affinities of GPCRs to interact can be obtained from 'saturation' BRET studies [36,37]. In such experiments, forms of GPCRs C-terminally tagged with Renilla luciferase and with an autofluorescent protein that is able to act as an energy acceptor of light emitted from substrate oxidation by the luciferase are co-expressed in various ratios and the BRET signal is monitored. Co-expression of hCXCR2-Renilla luciferase and hCXCR2-GFP2 in HEK-293 cells resulted in BRET following addition of the luciferase substrate DeepBlueC (Figure 2C). At low energy acceptor (hCXCR2-GFP2) to energy donor (hCXCR2-Renilla luciferase) ratios the BRET signal increased with increasing [acceptor] to [donor] ratios, but this asymptotically approached a maximal value at higher [acceptor] to [donor] ratios (Figure 2C). Half-maximal BRET signal (BRET50) was achieved at an [acceptor] to [donor] ratio of 1.6+/-0.1. Co-expression of hDOP-Renilla luciferase and hDOP-GFP2 also generated BRET signals that saturated with increasing [acceptor] to [donor] ratios, in this case with BRET50=2.2+/-0.07. Co-expression of hDOP-Renilla luciferase with hCXCR2-GFP2 generated BRET signals that saturated, and in this case BRET50 was 0.34+/-0.02 (Figure 2C). These results are consistent with hCXCR2-hDOP hetero-interactions occurring with an even higher affinity than the corresponding hCXCR2-hCXCR2 and hDOP-hDOP homo-interactions.
###end p 38
###begin title 39
Co-expression of FLAG-hCXCR2 and c-Myc-hDOP allows their co-immunoprecipitation
###end title 39
###begin p 40
HEK-293 cells were mock-transfected (Mock) or transfected to transiently express FLAG-hCXCR2, c-Myc-hDOP or both (Co-transfected). Samples containing either FLAG-hCXCR2 or c-Myc-hDOP were also mixed (Mix). Confirmation of expression of the appropriate constructs was obtained by immunoblotting cell lysates with either anti-c-Myc or anti-FLAG antibodies (lower panels). Cell lysates were subsequently immunoprecipitated using anti-FLAG. Immunoprecipitated samples were resolved by SDS/PAGE and immunoblotted with an anti-c-Myc antibody (upper panel). Two further experiments produced similar results. IP, immunoprecipitation. The molecular mass in kDa is indicated on the left-hand side.
###end p 40
###begin title 41
FRET and BRET studies confirm hetero-interactions between co-expressed hCXCR2 and hDOP receptors
###end title 41
###begin p 42
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 232 234 232 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3+</sup>
###xml 441 442 441 442 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 742 743 742 743 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 766 767 766 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 784 791 784 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 817 818 817 818 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 831 838 831 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 862 863 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 881 888 876 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 912 913 907 908 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1017 1018 1012 1013 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
(A) shows tr-FRET. c-Myc-hDOP and FLAG-hDOP or c-Myc-hCXCR2 and FLAG-hDOP were expressed individually in HEK-293 cells that were then mixed (mix) or the two receptors were co-expressed (Co). Following addition of a combination of Eu3+-labelled anti-c-Myc, to act as a long-lived energy donor, and APC-labelled anti-FLAG, to act as a potential energy acceptor, to intact cells tr-FRET was monitored as described in the Experimental section. (B) shows FRET imaging. hDOP-eYFP (eYFP) was transiently expressed in HEK-293 cells with (lower panels) or without (upper panels) hCXCR2-eCFP (eCFP) and fluorescence imaged. Raw FRET (FRET) and calculated normalized FRET (right-hand panels) was then assessed as described in the Experimental section. (C) shows saturation BRET2 studies. hCXCR2-Renilla luciferase and hCXCR2-GFP2 (), hCXCR2-Renilla luciferase and hDOP-GFP2 (square) or hDOP-Renilla luciferase and hDOP-GFP2 (o) were transiently co-expressed in HEK-293 cells. Following addition of the luciferase substrate/BRET2 energy donor DeepBlueC, BRET measurements were made. Donor and acceptor ratios were assessed as described in the Experimental section. Each experiment is representative of three.
###end p 42
###begin p 43
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 290 297 290 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 517 523 513 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i</sub>
###xml 596 598 588 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 648 650 640 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 663 670 655 658 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 691 699 679 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 759 761 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 802 804 790 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 807 809 795 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 830 832 818 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 905 913 893 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 974 975 962 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1022 1029 1010 1013 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1058 1059 1042 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1059 1060 1043 1044 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 1112 1113 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1113 1114 1095 1096 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 1452 1454 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1481 1488 1463 1466 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1584 1586 1562 1564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1733 1740 1711 1714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1742 1750 1716 1724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1812 1819 1786 1789 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i1</sub>
###xml 1829 1831 1799 1801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1875 1882 1845 1848 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1905 1912 1871 1874 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1973 1975 1935 1937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 2099 2107 2061 2069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 2334 2336 2296 2298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 2395 2397 2357 2359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
Over time, we have generated a wide range of GPCR-G-protein fusion constructs [38,39]. These allow production, from single open reading frames, of bi-functional polypeptides containing the sequence of both a receptor and a G-protein. A C352I [40,41] pertussis-toxin-insensitive variant of Galphai2 was linked in-frame to the C-terminal tail of the hDOP receptor. Following transient expression in HEK-293 cells, treatment with pertussis toxin (25 ng/ml for 16 h), to cause ADP-ribosylation of endogenously expressed Galphai G-proteins, and membrane preparation, the synthetic enkephalin DADLE (10-6 M) caused a 4-5-fold increase in the binding of [35S]GTP[S] in Galphai2 immunoprecipitates (Figure 3A). By contrast, the non-peptide CXCR2 antagonist SB225002 [42] had no effect at concentrations from 10-9-10-5 M and, indeed, at 10-5 M it had a limited capacity to inhibit the stimulatory effect of DADLE (Figure 3A). The capacity of both DADLE and SB225002 to compete with [3H]diprenorphine for binding to the hDOP-C352I Galphai2 fusion protein indicated a pKi for DADLE of 9.0+/-0.09, whereas for SB225002 the pKi was >4.0 (results not shown). Pairs of GPCR-G-protein fusions that are individually both inactive due to the introduction of mutations can reconstitute function when co-expressed if the GPCRs form a dimer and if one of the fusion proteins is mutated in the receptor whereas the other contains the inactivating mutation in the G-protein [30]. Variants of hDOP-C352I Galphai2 that did not modify the ligand-binding domain but failed to increase significantly binding of [35S]GTP[S] in response to DADLE were produced by mutation of either V150E+V154D in the receptor element or by introduction of a G204A mutation into Galphai2 (Figure 3B). As demonstrated previously for the equivalent hDOP-C351I Galphai1 mutants [30], co-expression of V150E,V154D hDOP-C352I Galphai2 and hDOP-G204A,C352I Galphai2 reconstituted the ability of DADLE to stimulate binding of [35S]GTP[S] in membranes of pertussis-toxin-treated HEK-293 cells, whereas SB225002 was again unable to replicate this effect (Figure 3B). The effect of DADLE required co-expression of the two individually non-responsive fusion constructs. Simple mixing of membranes expressing each construct individually did not result in a substantial increase in binding of [35S]GTP[S] in response to DADLE (results not shown, but see [30]).
###end p 43
###begin title 44
###xml 6 13 6 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
hDOP-Galphai2 fusion proteins are activated by DADLE but not by SB225002
###end title 44
###begin p 45
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 18 25 18 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 185 187 181 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 200 207 196 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 266 268 258 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 307 309 299 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 312 314 304 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 330 332 322 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 348 350 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 369 370 361 362 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 396 403 388 391 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 426 433 414 417 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 576 578 560 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 591 598 575 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 657 658 637 638 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 707 708 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(A) A hDOP-C352I Galphai2 fusion protein was expressed transiently in HEK-293 cells. Following pertussis-toxin treatment (25 ng/ml for 16 h) and membrane preparation, basal binding of [35S]GTP[S] in Galphai2 immunoprecipitates (Basal) and its regulation by DADLE (10-6 M), concentrations of SB225002 from 10-5-10-9 M and DADLE (10-6 M)+SB225002 (10-5 M) was assessed. (B) V150E,V154D hDOP-C352I Galphai2 and hDOP-G204A,C352I Galphai2 were co-expressed transiently in HEK-293 cells. Following pertussis-toxin treatment (25 ng/ml for 16 h) and membrane preparation, binding of [35S]GTP[S] in Galphai2 immunoprecipitates in response to the same ligands as in (A) was measured. Values represent means+/-S.E.M. (n=3).
###end p 45
###begin p 46
###xml 34 41 34 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 198 200 194 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 213 220 209 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 286 288 278 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 304 312 294 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 380 388 370 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 516 518 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 555 557 545 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 587 594 577 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 603 611 589 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 644 651 630 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 746 753 728 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 814 822 792 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1011 1013 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1039 1046 1017 1020 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1086 1094 1060 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
We next generated a hCXCR2-C352I Galphai2 fusion construct. Following transient expression in HEK-293 cells, pertussis-toxin treatment and membrane preparation, IL-8 was able to promote binding of [35S]GTP[S] in Galphai2 immunoprecipitates in a concentration-dependent manner with a pEC50 of -7.4+/-0.2 (Figure 4A). This effect of IL-8 was blocked by the co-addition of SB225002 (Figure 4B), whereas each of DADLE, the DOP opioid receptor selective DPDPE and the highly DOP receptor selective small molecule SNC162 [28] were unable to promote binding of [35S]GTP[S] to the hCXCR2-C352I Galphai2 fusion (Figure 4B). As noted for the hDOP-C352I Galphai2 construct, introduction of the G204A mutation into the G-protein element of the hCXCR2-C352I Galphai2 fusion protein essentially eliminated the response to IL-8 (Figure 4C). The same was true when, based on sequence comparisons and a central role for hydrophobic residues in the second intracellular loop of class A GPCRs in agonist activation of G-proteins [43], an I148E hCXCR2-C352I Galphai2 construct was generated and expressed (Figure 4C).
###end p 46
###begin title 47
###xml 26 33 26 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
Analysis of hCXCR2-C352I Galphai2 fusion proteins
###end title 47
###begin p 48
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 18 25 18 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 164 166 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 179 186 175 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 271 272 263 264 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 275 277 267 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 324 325 316 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 350 352 342 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 366 368 358 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 489 491 481 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 505 506 497 498 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 528 535 520 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 559 566 547 550 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 706 708 690 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 721 728 705 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 817 819 797 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 839 841 819 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 886 887 864 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(A) hCXCR2-C352I Galphai2 was expressed transiently in HEK-293 cells. Following pertussis-toxin treatment (25 ng/ml for 16 h) and membrane preparation, binding of [35S]GTP[S] in Galphai2 immunoprecipitates was measured in the presence of various concentrations of IL-8. (B) [35S]GTP[S] binding studies were performed as in (A) in the presence of 3x10-7 M IL-8, or 10-6 M of each of DADLE, DPDPE or SNC162 (open bars). In the solid bars the experiments were repeated with the addition of 10-6 M SB225002. (C) hCXCR2-G204A,C352I Galphai2 or hI148E CXCR2-C352I Galphai2 were expressed transiently in HEK-293 cells. Following pertussis-toxin treatment (25 ng/ml for 16 h) and membrane preparation, binding of [35S]GTP[S] in Galphai2 immunoprecipitates was measured in the absence of ligand (Basal) or the presence of 3x10-7 M IL-8 (IL-8) or 10-6 M DADLE (DADLE). Values are means+/-S.E.M. (n=3).
###end p 48
###begin p 49
###xml 23 30 23 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 146 153 142 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 261 268 253 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 547 555 535 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 632 640 620 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 699 707 687 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 720 722 708 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 747 749 735 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 762 769 750 753 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 950 958 934 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1022 1024 1006 1008 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1031 1039 1015 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1107 1114 1091 1094 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1253 1262 1233 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figures 1</xref>
###xml 1267 1268 1247 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 1347 1349 1327 1329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1400 1402 1380 1382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1474 1476 1454 1456 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1484 1492 1464 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1576 1578 1556 1558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1677 1679 1657 1659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1698 1700 1678 1680 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1723 1731 1703 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1882 1890 1862 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1928 1930 1908 1910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1933 1941 1913 1921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
FLAG-hDOP-G204A,C352I Galphai2 was next expressed stably and constitutively in Flp-In T-REx HEK-293 cells that harboured c-Myc-I148E-CXCR2-C352I Galphai2 at the Flp-In locus and individual clones were isolated. These cells should allow c-Myc-I148E-CXCR2-C352I Galphai2 expression to be controlled in an entirely tetracycline/doxycycline 'on' fashion. This expectation was confirmed via immunocytochemistry. Although plasma-membrane-localized anti-FLAG immunoreactivity was observed in these cells both with and without treatment with doxycycline (Figure 5A), anti-CXCR2 reactivity was only observed following doxycycline treatment (Figure 5A) and this overlapped strongly with the anti-FLAG signal (Figure 5A). DADLE (10-6 M) promoted binding of [35S]GTP[S] in Galphai2 immunoprecipitates from membranes of pertussis-toxin-treated cells of this clone that had been exposed to doxycycline, but not in those that had not been treated with doxycycline (Figure 5B). This occurred in a concentration-dependent manner with a pEC50=-7.2 (Figure 5C). This can only reflect guanine-nucleotide exchange on the C352I Galphai2 linked to c-Myc-I148E CXCR2 and is entirely consistent with the other observations of hCXCR2-hDOP opioid receptor hetero-oligomerization (Figures 1 and 2). Although without effect in the absence of DADLE, co-addition of SB225002 (10-6 M) resulted in higher levels of DADLE-stimulated [35S]GTP[S] binding without altering the potency of the opioid agonist (pEC50=-7.1) (Figure 5C). When similar experiments were performed with a single concentration of DADLE (10-6 M), increasing concentrations of SB225002 resulted in an increase in DADLE-stimulated binding of [35S]GTP[S] with a pEC50 of -7.2 for SB225002 (Figure 5D). These effects were not restricted to DADLE. Entirely analogous effects of SB225002 were observed when either a second synthetic enkephalin, DPDPE (Figure 5D), or the non-peptide ligand SNC162 [28] (Figure 5D) were used as agonists at the DOP receptor.
###end p 49
###begin title 50
###xml 49 56 49 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 99 106 95 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
Inducible expression of c-Myc-I148E-CXCR2-C352I Galphai2 in the presence of FLAG-hDOP-G204A,C352I Galphai2 results in their co-localization at the surface of Flp-In T-REx HEK-293 cells and G-protein activation by DADLE
###end title 50
###begin p 51
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 86 93 86 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 160 167 156 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 286 288 273 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i2</sub>
###xml 355 362 342 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 437 438 420 421 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 474 475 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 658 660 640 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 673 680 655 658 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 765 767 743 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 773 774 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 864 865 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 873 874 851 852 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1000 1002 978 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1015 1022 993 996 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1105 1107 1079 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1125 1126 1099 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1219 1220 1193 1194 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1274 1276 1248 1250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1289 1296 1263 1266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1337 1339 1307 1309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1448 1449 1411 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(A) Flp-In T-REx HEK-293 cells were generated that harboured c-Myc-I148E-CXCR2-C352I Galphai2 at the Flp-In locus and constitutively expressed FLAG-hDOP-C352I Galphai2. Cells were treated with (lower panels) or without (upper panels) doxycycline (1 mug/ml, 48 h). FLAG-hDOP-C352I Galphai2 (green) was detected using anti-FLAG and c-Myc-I148E-CXCR2-C352I Galphai2 (red) with anti-CXCR2. Merged images are also shown (right-hand panels). (B) Flp-In T-REx HEK-293 cells as in (A) were treated (+Dox) or not (-Dox) with doxycycline (1 mug/ml, 48 h) and with pertussis toxin (25 ng/ml) for the last 16 h. Membranes of these cells were used to measure binding of [35S]GTP[S] in Galphai2 immunoprecipitates in the absence (open bars) and presence (solid bars) of DADLE (10-6M). **P<0.001, significantly greater after treatment with doxycycline (measured using the paired t test. (C) Membranes of the above doxycycline- and pertussis-toxin-treated Flp-In T-REx HEK-293 cells were used to measure binding of [35S]GTP[S] in Galphai2 immunoprecipitates in response to varying concentrations of DADLE () and DADLE+10-6M SB225002 (). **P<0.001, significant enhancement in the presence of SB225002 (measured using one-way ANOVA). (D) Membranes as above were used to measure binding of [35S]GTP[S] in Galphai2 immunoprecipitates in the presence of 10-6M DADLE (), DPDPE (square) or SNC162 () and various concentrations of SB225002. Values are means+/-S.E.M. (n=3).
###end p 51
###begin p 52
###xml 60 67 60 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 159 166 155 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 248 255 240 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 466 474 453 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 505 512 492 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 693 701 676 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 757 764 740 743 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 938 946 917 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 984 991 963 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1065 1072 1040 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1085 1093 1056 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1182 1184 1153 1155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1352 1354 1323 1325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1367 1374 1338 1341 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1542 1549 1509 1512 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 1568 1576 1531 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
Because of the ability to control c-Myc-I148E hCXCR2-C352I Galphai2 expression in these cells in the face of constitutive expression of FLAG-hDOP-G204A,C352I Galphai2, we therefore examined the time course of induction of c-Myc-I148E hCXCR2-C352I Galphai2 expression following addition of doxycycline (1 mug/ml) to these cells. Immunoblotting cell lysates with an anti-c-Myc antibody confirmed a lack of expression of this polypeptide without doxycycline treatment (Figure 6A). c-Myc-I148E h CXCR2-C352I Galphai2 expression could be detected within 6 h of doxycycline treatment, but at that time the fusion protein was present largely as an immature form that lacked terminal N-glycosylation (Figure 6A). By 24 h, higher levels of c-Myc-I148E hCXCR2-C352I Galphai2 were present and a substantial amount of this polypeptide was terminally N-glycosylated. This pattern was maintained in the presence of doxycycline for up to at least 96 h (Figure 6A). Levels of FLAG-hDOP-G204A, C352I Galphai2 expression were unaffected by the induction of c-Myc-I148E hCXCR2-C352I Galphai2 expression (Figure 6A). As anticipated, without doxycycline treatment, DADLE could not stimulate binding of [35S]GTP[S] in membranes of these cells following pertussis-toxin treatment, whereas with time of doxycycline treatment, both the capacity of DADLE to elevate binding of [35S]GTP[S] in Galphai2 immunoprecipitates and the effect of SB225002 to enhance G-protein activation in response to DADLE mirrored the time course of appearance of c-Myc-I148E hCXCR2-C352I Galphai2 immunoreactivity (Figure 6B).
###end p 52
###begin title 53
The effect of SB225002 requires expression of hCXCR2
###end title 53
###begin p 54
###xml 67 74 67 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 141 148 137 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 324 325 315 316 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 362 369 353 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 404 411 391 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 428 429 411 412 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 511 513 494 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 526 533 509 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 581 583 560 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 633 635 612 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 653 654 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 663 664 642 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Flp-In T-REx HEK-293 cells that harboured c-Myc-I148E-CXCR2-C352I Galphai2 at the Flp-In locus and constitutively expressed FLAG-hDOP-C352I Galphai2 were treated for various times with doxycycline (1 mug/ml). Following pertussis-toxin treatment and membrane preparation, samples were resolved by SDS/PAGE and immunoblotted (A) to detect c-Myc-I148E-CXCR2-C352I Galphai2 (upper panel) or FLAG-hDOP-C352I Galphai2 (lower panel). (B) Membranes of these cells were then used to assess basal binding (open bars) of [35S]GTP[S] in Galphai2 immunoprecipitates and the effects of DADLE (10-6 M; light-grey bars) or DADLE+SB225002 (both at 10-6 M; black bars). *P<0.01, **P<0.001 (as compared with control; measured using one-way ANOVA).
###end p 54
###begin p 55
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 612 620 612 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 734 742 734 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 848 856 848 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 961 963 961 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1036 1044 1036 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1095 1097 1095 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1166 1174 1166 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1256 1258 1256 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1285 1287 1285 1287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1297 1306 1297 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figures 7</xref>
###xml 1312 1313 1312 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">7</xref>
###xml 1373 1375 1373 1375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1382 1390 1382 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1422 1424 1422 1424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1598 1606 1598 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
Although a highly effective means to explore these receptor co-expression-dependent heterodimer-specific [25,44] allosteric effects of CXCR2 antagonists on DOP receptor function, the fusion proteins are artificial constructions [45,46]. Hence, to explore these effects further we generated extra Flp-In T-REx HEK-293 cell lines in which hCXCR2 N-terminally tagged with VSV-G was cloned into the inducible locus and in which FLAG-hDOP was expressed constitutively. As anticipated, anti-FLAG immunocytochemistry demonstrated the presence of FLAG-hDOP both without and with treatment of the cells with doxycycline (Figure 7A). In contrast, anti-VSV-G immunoreactivity was only detected following treatment of the cells with doxycycline (Figure 7A) and merging of the images indicated co-localization of VSV-G-hCXCR2 and FLAG-hDOP at the cell surface (Figure 7A). In membranes derived from both untreated and doxycycline-treated cells, DADLE-stimulated binding of [35S]GTP[S] was blocked by the general opioid receptor antagonist naloxone (Figure 7B). However, although DADLE-stimulated binding of [35S]GTP[S] in membranes of untreated cells was unaffected by SB225002 (Figure 7B), in doxycycline-treated cells SB225002 again enhanced the capacity of DADLE (10-6 M) to promote binding of [35S]GTP[S] (Figures 7B and 7C) and did so in a concentration-dependent manner with a pEC50=-8.1 (Figure 7C). IL-8 stimulated binding of [35S]GTP[S] only in membraness of doxycycline-treated cells and, in contrast with the effect of DADLE, SB225002 blocked the effect of IL-8, whereas naloxone was without effect (Figure 7C).
###end p 55
###begin title 56
Production and characterization of Flp-In T-REx HEK-293 cells harbouring VSV-G-hCXCR2 and constitutively expressing FLAG-hDOP: SB225002 enhances the function of an opioid agonist in cells co-expressing hDOP and hCXCR2
###end title 56
###begin p 57
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 711 712 710 711 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 761 762 760 761 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 909 911 908 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 925 927 924 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 943 945 942 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 959 961 958 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 977 979 976 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 992 994 991 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1007 1009 1006 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1025 1027 1024 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1042 1044 1041 1043 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1061 1063 1060 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 1096 1098 1095 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1149 1150 1148 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1216 1217 1207 1208 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1331 1333 1322 1324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1366 1368 1357 1359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
(A) Flp-In T-REx HEK-293 cell lines were created in which hCXCR2 which was N-terminally tagged with VSV-G was cloned into the inducible locus and in which FLAG-hDOP was expressed constitutively. Cells were treated with (lower panels) or without (upper panels) doxycycline (1 mug/ml, 48 h). Anti-FLAG immunocytochemistry (red) demonstrated the presence of FLAG-hDOP both without and with treatment of the cells with doxycycline. In contrast, anti-VSV-G immunoreactivity (green) was only detected following treatment of the cells with doxycycline. Merging of the images (right-hand panels) indicated co-localization of VSV-G-hCXCR2 and FLAG-hDOP (yellow) at the cell surface when both constructs were expressed. (B) Membranes of Flp-In T-REx HEK-293 cells as in (A) were used both without (open bars) or following doxycycline induction of VSV-G-hCXCR2 expression (solid bars) to measure the ability of DADLE (10-6 M), DADLE (10-6 M)+SB225002 (10-6 M), DADLE (10-6 M)+naloxone (10-5 M), IL-8 (10-8 M), IL-8 (10-8 M)+SB225002 (10-6 M) or IL-8 (10-8 M) +naloxone (10-5 M) to enhance basal binding of [35S]GTP[S]. **SB225002 enhances the effect of DADLE (P<0.001); not equal, SB225002 does not have a significant effect. (C) Following doxycycline induction of VSV-G-hCXCR2 expression, membranes as above were used to measure binding of [35S]GTP[S] in response to DADLE (10-6 M) in the presence of various concentrations of SB225002.
###end p 57
###begin title 58
DISCUSSION
###end title 58
###begin p 59
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 610 612 610 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 910 912 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 678 681 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
GPCRs are the most tractable class of therapeutic targets for the design and development of small-molecule therapeutic medicines and it has been estimated that some 30-50% of clinically available drugs target the function of GPCR family members [47,48]. All but two of the medicines that interact directly with a GPCR do so via the orthosteric binding site, i.e. the binding site for the natural ligand, and function either to mimic or block the action of the natural ligand [25]. Despite this, and due in part to the clinical effectiveness of cinacalcet, that acts as a positive allosteric modulator of the Ca2+-sensing receptor [49,50], and the recent development of the anti-HIV medicine maraviroc that acts as a CCR5 receptor-directed negative allosteric regulator [25,51], there is now considerable interest in understanding the basis and mode of action of ligands that bind to allosteric sites on GPCRs [52-54]. This reflects, in part, that true allosteric ligands are anticipated to function only in the presence of an orthosteric agonist and to modulate the effectiveness of signal transduction. To date, virtually all studies on allosteric regulators of GPCRs have focused on modulators that bind to the same GPCR as the orthosteric ligand but at a separate location. This reflects a combination of the traditional view that GPCRs exist and function as non-interacting monomeric species and that ligand screening strategies concentrate on analysis of the function of a single GPCR expressed in isolation.
###end p 59
###begin p 60
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 626 633 626 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 888 890 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 1108 1110 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
It is now widely accepted that GPCRs can form dimers and/or higher-order oligomers and that dimerization is probably integral to function [16,55]. Although the majority of early studies concentrated on homodimerization, i.e. interactions between multiple copies of the same GPCR, there has been a growing base of evidence to support the concept that GPCR heterodimerization can occur and that it is relevant to physiological function. Given the widespread co-expression of many GPCRs, such 'heterodimers' are being considered as novel sets of therapeutic targets. Indeed, as the multiplicity of opioid receptor pharmacologies in vivo are far too complex to be explained by individual monomers, or indeed homodimers, of the molecularly defined DOP, KOP and MOP receptors, there is a large literature on how opioid receptor heterodimerization may help to explain this complex pharmacology [56,57]. Furthermore, based on the co-expression patterns of opioid receptor subtypes, apparently orthosteric ligands have been reported to show considerable selectivity for specific opioid receptor heterodimer pairings [58].
###end p 60
###begin p 61
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
In a GPCR heterodimer, it might be anticipated that the binding of a ligand to the orthosteric site of one GPCR could alter the pharmacology and function of the orthosteric binding site of the partner GPCR [25]. In such a situation the ligand at the first GPCR would act as an allosteric agent for the orthosteric agonist of the second GPCR and this would be a heterodimer-specific effect [25] because the ligand would display no direct effect on the second GPCR in assays in which the second GPCR was expressed alone. This concept has important implications for the design, identification and use of novel small-molecule regulators of GPCRs. For example, the allosteric effect of such ligands would be restricted to cells and tissues in which the GPCR heterodimer is present and would only be detected in assays in which the relevant target GPCR heterodimer is present [25].
###end p 61
###begin p 62
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 480 483 480 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 701 704 701 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1354 1356 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1410 1412 1401 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
Although this concept has not been explored widely, there are a number of reports consistent with such a mechanism. For example, in cells co-expressing the CCR2b and CCR5 chemokine receptors CCR5-specific ligands that are unable to compete for MCP-1 binding on cells expressing CCR2b alone, and hence presumable do not bind directly to CCR2b, were able to prevent efficiently MCP-1 binding when the two receptors were co-expressed [26]. In a similar vein, binding of the agonist [125I]melatonin to the MT1 receptor was eliminated when the orphan GPCR GPR50 was co-expressed along with the melatonin MT1 receptor [27]. Furthermore, in cells natively co-expressing GPR50 and the MT1 receptor, specific [125I]melatonin binding could not be observed until GPR50 levels were reduced via a siRNA (small interfering RNA)-based approach [27]. GPR50 is related to the MT1 receptor and these workers also provided a series of observations consistent with their heterodimerization [27]. Perhaps even more interesting from a therapeutic standpoint, the cannabinoid CB1 receptor orthosteric antagonist/inverse agonist rimonabant (marketed as Acompliatrade mark), which has been approved in Europe for the treatment of obesity, decreases the potency of the orexigenic peptide orexin A only when the cannabinoid CB1 receptor is co-expressed with the orexin-1 receptor [33] and these two GPCRs effectively form a heterodimer [33].
###end p 62
###begin p 63
###xml 468 469 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 448 453 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 537 542 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As noted earlier, opioid receptors are widely expressed by white blood cells and there is a substantial literature on functional interactions between opioid ligands and chemokines in the regulation of white-cell chemotaxis. Prior to the present studies there have also been reports of direct physical interactions between opioid and chemokine receptors. Previously, these have concentrated on the CCR5 receptor due to its role as a co-receptor for HIV-1 entry into CD4+ white cells and the susceptibility of opiate addicts to succumb to HIV-1 infection. Furthermore, very recent studies by Pello et al. [59] have shown that interactions between the chemokine CXCR4 receptor and the DOP receptor have functional consequences in immune cells in that co-addition of agonist ligands for these receptors fail to generate function, leading to a suppression of signalling potentially because the heterodimer produces a dominant-negative effect.
###end p 63
###begin p 64
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
Therefore our initial studies centred on obtaining evidence for physical interactions between the CXCR2 receptor and the DOP opioid receptor. This was achieved by a combination of co-immunoprecipitation and various intact cell resonance energy transfer techniques, whereas the use of so-called 'saturation' BRET studies [36,37] suggested that CXCR2 receptor-DOP opioid receptor hetero-interactions may display higher avidity than either corresponding homo-interaction. This concept is not without parallel. Work on melatonin receptor subtypes has indicated greater avidity of hetero-interactions between the MT1 and MT2 receptors than the corresponding MT1-MT1 or MT2-MT2 homo-interactions [60].
###end p 64
###begin p 65
###xml 26 28 26 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 29 31 29 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 50 52 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B62">62</xref>
###xml 510 512 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 513 515 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B63">63</xref>
For a number of years we [38,39] and others (see [61,62] for review) have employed fusion proteins, in which a G-protein alpha subunit is linked in-frame to the C-terminal tail of a GPCR to generate chimaeric, bi-functional polypeptides to explore many aspects of GPCR and G-protein function and pharmacology. We have also used this approach to examine GPCR homodimerization by demonstrating reconstitution of function only upon co-expression of pairs of GPCR-G-protein fusions that are individually inactive [30,63]. When we co-expressed pairs of such fusion proteins in which, in the first, the CXCR2 receptor was not signal-transduction-competent because of the introduction of a mutation into the second intracellular loop, whereas in the second the DOP receptor was wild-type but the linked G-protein was modified to prevent guanine-nucleotide exchange, DOP agonists were able to cause activation of the wild-type G-protein linked to the CXCR2 receptor in a concentration-dependent manner. Furthermore, following co-expression of this pairing, a CXCR2 antagonist was able to enhance the maximal activity of a range of DOP receptor agonists with distinct chemotypes. We also attempted to explore whether the CXCR2 agonist IL-8 also modulated the function or potency of DOP receptor agonists. However, we were unable to observe such effects (results not shown). The reasons for this are unclear. It could be hypothesized that an agonist ligand might have a greater effect on the structure/function of the partner GPCR of the heterodimer because agonist ligands must alter the conformation of their own target receptor to initiate signal transduction. Such an effect might then alter the orthosteric binding pocket or function of the GPCR heterodimer partner. However, it is impractical at this stage to speculate on the basis or implications of our inability to detect such an effect, not least because of the size and structural differences between the peptide agonist IL-8 and the synthetic small-molecule CXCR2 blocker employed.
###end p 65
###begin p 66
###xml 247 254 247 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 339 346 335 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
###xml 443 450 435 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;i2</sub>
Key experiments employed Flp-In T-REx HEK-293 cells. These contain a single site of chromosomal integration from which constructs cloned into this locus can be expressed in a completely inducible fashion. In these studies c-Myc-I148E CXCR2-C352I Galphai2 was harboured at the Flp-In locus, whereas in the same cells FLAG-hDOP-G204A,C352I Galphai2 was expressed stably and constitutively. Antibiotic-induced turn-on of c-Myc-I148E CXCR2-C352I Galphai2 expression was required to observe both DOP receptor function and the positive allosteric effects of the CXCR2 antagonist on this. Initial preliminary studies had confirmed that the DOP ligands had no direct effect at the CXCR2 receptor and that the CXCR2 antagonist had no direct effects at the DOP receptor, indicating the allosteric effects to be heterodimer specific. Importantly, as well as requiring expression of CXCR2, the allosteric effects of the CXCR2 antagonist were produced in a concentration-dependent fashion and with affinity consistent with its occupancy of the CXCR2 orthosteric binding site.
###end p 66
###begin p 67
Although these key experiments were performed using pairs of GPCR-G-protein fusions it is important to note that entirely equivalent results were produced when Flp-In T-REx HEK-293 cells were established in which the unfused wild-type hDOP receptor was expressed constitutively and the unfused mutant hCXCR2 receptor could be produced, on demand, from the Flp-In T-REx locus.
###end p 67
###begin p 68
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
The present studies provide clear biochemical, biophysical and now pharmacological evidence to indicate the capacity of CXCR2 and DOP opioid receptors to interact physically. They also clearly indicate the capacity of GPCR heterodimers to provide novel allosteric pharmacology. Detection of such activities in ligand screening campaigns will be a challenge because they will be identified by neither primary screens, nor secondary counter screens, in which individual GPCRs are expressed and studied 'one target at a time' [25]. However, such heterodimer specific allosteric ligands offer obvious opportunities, modulating the function of the partner GPCR only in the presence of the orthosteric ligand for that receptor and doing so only in cells and tissues in which the relevant heterodimer is expressed [25]. It will be interesting to see if this principle can be exploited therapeutically.
###end p 68
###begin p 69
These studies were supported by the BBSRC (Biosciences and Biotechnology Research Council), Cara Therapeutics and the Wellcome Trust.
###end p 69
###begin article-title 70
Opioid G protein-coupled receptors: signals at the crossroads of inflammation
###end article-title 70
###begin article-title 71
Expression of opioid receptors during peripheral inflammation
###end article-title 71
###begin article-title 72
Peripherally restricted opioid agonists as novel analgesic agents
###end article-title 72
###begin article-title 73
Opioid receptors and their ligands
###end article-title 73
###begin article-title 74
Detection and function of opioid receptors on cells from the immune system
###end article-title 74
###begin article-title 75
Chemokines, chemokine receptors and pain
###end article-title 75
###begin article-title 76
Chemokines: integrators of pain and inflammation
###end article-title 76
###begin article-title 77
Chemokines and pain
###end article-title 77
###begin article-title 78
Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization
###end article-title 78
###begin article-title 79
Bidirectional heterologous desensitization of opioid and chemokine receptors
###end article-title 79
###begin article-title 80
Interactions of opioid receptors, chemokines, and chemokine receptors
###end article-title 80
###begin article-title 81
Interactions of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells
###end article-title 81
###begin article-title 82
Heterodimerization and cross-densitization between the m-opioid receptor and the chemokine CCR5 receptor
###end article-title 82
###begin article-title 83
Chemokine receptors
###end article-title 83
###begin article-title 84
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury
###end article-title 84
###begin article-title 85
GPCR dimerisation
###end article-title 85
###begin article-title 86
The G protein-coupled receptor rhodopsin in the native membrane
###end article-title 86
###begin article-title 87
###xml 81 83 77 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1b</sub>
Multiple interactions between transmembrane helices generate the oligomeric alpha1b-adrenoceptor
###end article-title 87
###begin article-title 88
###xml 9 11 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1b</sub>
The alpha1b-adrenoceptor exists as a higher-order oligomer: effective oligomerization is required for receptor maturation, surface delivery and function
###end article-title 88
###begin article-title 89
Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting
###end article-title 89
###begin article-title 90
The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities
###end article-title 90
###begin article-title 91
GPCR hetero-dimers: pharmacology, function and relevance to drug discovery
###end article-title 91
###begin article-title 92
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia
###end article-title 92
###begin article-title 93
Ligand-independent CXCR2 dimerization
###end article-title 93
###begin article-title 94
Allosteric modulation of hetero-dimeric GPCRs
###end article-title 94
###begin article-title 95
Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers
###end article-title 95
###begin article-title 96
(2006) The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization
###end article-title 96
###begin article-title 97
###xml 121 140 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
delta-Opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats
###end article-title 97
###begin article-title 98
###xml 78 79 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sub>
###xml 85 86 85 86 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
Differential regulation of levels of the guanine nucleotide binding proteins Gi and Go in neuroblastoma x glioma hybrid cells in response to dibutyryl cAMP
###end article-title 98
###begin article-title 99
Functional complementation and the analysis of opioid receptor homo-dimerization
###end article-title 99
###begin article-title 100
###xml 146 151 <span type="species:ncbi:9606">human</span>
Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer: the human delta opioid receptor displays constitutive oligomerization at the cell surface which is not regulated by receptor occupancy
###end article-title 100
###begin article-title 101
Up-regulation of the angiotensin II AT1 receptor by the Mas proto-oncogene is due to constitutive activation of Gq/G11 by Mas
###end article-title 101
###begin article-title 102
Orexin-1 receptor-cannabinoid CB1 receptor hetero-dimerization results in both ligand-dependent and -independent co-ordinated alterations of receptor localization and function
###end article-title 102
###begin article-title 103
Interactions between the Mas-related receptors MrgD and MrgE alter signalling and regulation of MrgD
###end article-title 103
###begin article-title 104
Homo- and hetero-oligomeric interactions between G protein-coupled receptors in living cells monitored by two variants of bioluminesence resonance energy transfer. Hetero-oligomers between receptor subtypes form more efficiency than between less closely related sequences
###end article-title 104
###begin article-title 105
Methods to monitor the quaternary structure of G protein-coupled receptors
###end article-title 105
###begin article-title 106
Rigorous BRET analysis of GPCR oligomerization: newer does not mean better
###end article-title 106
###begin article-title 107
G protein-coupled receptor fusion proteins in drug discovery
###end article-title 107
###begin article-title 108
Novel pharmacological applications of G protein-coupled receptor-G protein fusions
###end article-title 108
###begin article-title 109
###xml 48 50 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i1</sub>
###xml 99 101 95 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2A</sub>
Hydrophobicity of residue 351 of the G-protein Gi1 determines the extent of activation by the alpha2A-adrenoceptor
###end article-title 109
###begin article-title 110
Comparative analysis of the efficacy of A1 adenosine receptor activation of Gi/oalpha G proteins following coexpression of receptor and G protein and expression of A1 adenosine receptor- Gi/oalpha fusion proteins
###end article-title 110
###begin article-title 111
Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration
###end article-title 111
###begin article-title 112
The G Protein-Coupled Receptors Handbook
###end article-title 112
###begin article-title 113
Allosteric properties of G protein-coupled receptor oligomers
###end article-title 113
###begin article-title 114
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 119 121 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o1</sub>
###xml 161 163 161 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i1</sub>
###xml 166 168 166 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i2</sub>
###xml 174 176 174 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i3</sub>
Protean agonism at the dopamine D2 receptor: S-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1, Gi2 and Gi3
###end article-title 114
###begin article-title 115
Missing links: mechanisms of protean agonism
###end article-title 115
###begin article-title 116
The druggable genome
###end article-title 116
###begin article-title 117
The 7 TM G-protein-coupled receptor target family
###end article-title 117
###begin article-title 118
Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism
###end article-title 118
###begin article-title 119
Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors
###end article-title 119
###begin article-title 120
###xml 146 181 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
###end article-title 120
###begin article-title 121
Keynote review: allosterism in membrane receptors
###end article-title 121
###begin article-title 122
Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox
###end article-title 122
###begin article-title 123
Allosteric modulation of G protein-coupled receptors
###end article-title 123
###begin article-title 124
G protein-coupled receptor dimerisation: molecular basis and relevance to function
###end article-title 124
###begin article-title 125
Opioids and their complicated receptor complexes
###end article-title 125
###begin article-title 126
Targeting opioid receptor heterodimers: strategies for screening and drug development
###end article-title 126
###begin article-title 127
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers
###end article-title 127
###begin article-title 128
Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation
###end article-title 128
###begin article-title 129
Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers
###end article-title 129
###begin article-title 130
Bring your own G protein
###end article-title 130
###begin article-title 131
Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits
###end article-title 131
###begin article-title 132
Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins
###end article-title 132

